pamrevlumab + corticosteroids

Pamrevlumab + corticosteroids is a combination therapy comprising **pamrevlumab**, a fully human monoclonal antibody targeting **connective tissue growth factor (CTGF)**, and a **systemic corticosteroid** (such as deflazacort or prednisone)[1][3][7]. Pamrevlumab inhibits CTGF to reduce pathological fibrosis and tissue remodeling, particularly in diseases where fibrotic progression impairs muscle function, such as Duchenne muscular dystrophy (DMD)[2][4][5][7]. Corticosteroids act as anti-inflammatory agents and are a standard background therapy in DMD[1][7]. This combination is under investigation, notably in Phase 2 and 3 clinical trials evaluating muscle function and progression in DMD patients, both ambulatory and non-ambulatory, typically receiving regular intravenous infusions of pamrevlumab alongside oral corticosteroids[1][3][5][7]. Pamrevlumab is not yet approved and its efficacy in combination with corticosteroids for DMD has not met all primary endpoints in clinical trials, but the therapy is generally well-tolerated[3][7]. The primary developer for pamrevlumab is FibroGen, and its mechanism of action centers on anti-fibrotic effects[2][4][5][7].

Other names

pamrevlumab + corticosteroids